Vor Bio (VOR)pharma announced that it has commenced an underwritten public offering of $100M of shares of its common stock. All of the shares are being offered by Vor Bio. J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept
- Vor Biopharma Appoints New Chief Medical Officer
- Vor Bio appoints Sokolove as Chief Medical Officer
- Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study
- Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split